Abbott Laboratories (ABT)
(Delayed Data from NYSE)
$119.39 USD
+1.50 (1.27%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $119.40 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$119.39 USD
+1.50 (1.27%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $119.40 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
Zacks News
Abbott (ABT) Stock Moves -0.24%: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed at $82.66 in the latest trading session, marking a -0.24% move from the prior day.
CGM Devices Gain Steam, Set New Trend in Diabetes Management
by Urmimala Biswas
The FDA authorization classifies the new type of CGM devices in class II and subjects these to certain criteria called special controls.
Abbott Receives European Nod for Pediatric Heart Devices
by Zacks Equity Research
Abbott (ABT) aims to offer better treatment options for the most vulnerable patient population.
Abbott Partners With Sanofi to Upgrade Diabetes Management
by Zacks Equity Research
Abbott (ABT) collaborates with Sanofi to revolutionize diabetes care through technological advancements.
Abbott (ABT) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed at $83.36 in the latest trading session, marking a -1.08% move from the prior day.
Abbott's (ABT) FreeStyle Libre Gains Canadian Reimbursement
by Zacks Equity Research
With this reimbursement approval, Abbott's (ABT) FreeStyle Libre becomes the first sensor-based glucose monitoring system to be listed by any provincial health plan in Canada.
Abbott Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Abbott Laboratories has been struggling lately, but the selling pressure may be coming to an end soon.
Abbott (ABT) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Abbott (ABT) closed at $83.19, marking a -1.22% move from the previous day.
Abbott (ABT) Launches Pivotal Trial TRILUMINATE in the US
by Zacks Equity Research
Given the lack of an alternative therapy to replace tricuspid regurgitation surgery, Abbott (ABT) should be at an advantage in this space.
Here's Why You Should Hold on to Thermo Fisher (TMO) for Now
by Zacks Equity Research
Investors continue to be optimistic about Thermo Fisher's (TMO) performance.
5 Cancer-Fighting Stocks to Add to Your Portfolio
by Zacks Equity Research
Cancer-fighting stocks receive a boost from advance research and development. These five stocks can add value to your portfolio.
Abbott (ABT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed the most recent trading day at $84.22, moving +0.68% from the previous trading session.
Here's Why You Should Add Abbott (ABT) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Abbott (ABT) on its balanced segmental performances.
Abbott's (ABT) TRACK-TBI Study Reveals Encouraging Results
by Zacks Equity Research
This study outcome should be a crucial step forward for Abbott Laboratories (ABT) in its endeavor to boost TBI diagnosis and treatment.
Has Abbott Laboratories (ABT) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (ABT) Outperforming Other Medical Stocks This Year?
Abbott (ABT) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Abbott (ABT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Abbott (ABT) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed the most recent trading day at $84.37, moving -0.62% from the previous trading session.
Abbott's Libre Adoption a Positive, Rhythm Management a Woe
by Zacks Equity Research
Abbott (ABT) is steadily riding high on a healthy growth track within its Diabetes Care business.
The Zacks Analyst Blog Highlights: Home Depot, Abbott, Bristol-Myers, Activision and Marathon
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Home Depot, Abbott, Bristol-Myers, Activision and Marathon
Tandem Diabetes Rides on t:slim X2 Uptake, Product Pipeline
by Zacks Equity Research
Robust domestic sales along with a strong unveiling of the t:slim X2 Insulin Pump in the international markets augur well for Tandem Diabetes (TNDM).
FDA OKs Medtronic's Evolut TAVR New Indication for Low Risk
by Zacks Equity Research
With the FDA's expanded indication nod, Medtronic's (MDT) Evolut TAVR platform now comes in handy for treating symptomatic severe aortic stenosis patients across all risk categories.
Top Stock Reports for Home Depot, Abbott & Bristol-Myers
by Mark Vickery
Today's Research Daily features updated research reports on 16 major stocks, including Home Depot (HD), Abbott (ABT) and Bristol-Myers (BMY).
Here's Why You Should Hold Onto IDEXX (IDXX) Stock for Now
by Zacks Equity Research
Investor confidence continues to be high on IDEXX Laboratories' (IDXX) prospects.
Abbott (ABT) Down 4.4% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Abbott (ABT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks.com featured highlights include: Abbott Laboratories, Baxter International, First Horizon National, OUTFRONT Media and ICF International
by Zacks Equity Research
Zacks.com featured highlights include: Abbott Laboratories, Baxter International, First Horizon National, OUTFRONT Media and ICF International